Skip to main content
. 2020 Nov 25;117(50):31780–31788. doi: 10.1073/pnas.2013615117

Fig. 5.

Fig. 5.

Analysis of tumor-infiltrating leukocytes (TILs) and tumor-draining lymph nodes (TDLNs). (A) Composition of the tumor-infiltrating immune cells, including the CD8:CD4 ratio, the proportions of AH1-specific CD8+ T cells and regulatory CD4+ T cells in WEHI-164 and CT26 tumors treated with saline, F8-4-1BBL, and combination therapy (αPD-1 and F8-4-1BBL). The proportions of AH1-specific CD8+ T cells and regulatory CD4+ T cells are shown also for matching TDLNs. (B) Composition of the TDLNs in WEHI-164 and CT26 tumor-bearing mice, including the CD8:CD4 ratio. (C) Phenotype of the CD8+ T cells and AH1-specific CD8+ T cells in CD26 tumor-bearing mice from different treatment groups. The phenotype was assessed based on the expression of CD62L, CD44, and the exhaustion markers CD39 and PD-1. The data represent individual values, means, and SDs. Statistical evaluations were performed using a regular two-way ANOVA followed by Tukey’s multiple comparison test using GraphPad Prism 8.4.1. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. APC, antigen-presenting cell; Treg, regulatory T cell; Teff, effector T cell (CD44+CD62L−); Tcm, central memory T cell (CD44+CD62L+); Tnaive, naïve T cell (CD44−CD62L+).